Compare Citius Pharmaceuticals Inc (CTXR) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares Semiconductor ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while iShares Semiconductor ETF trades at $559.57 (market cap $48.19B). The key difference: iShares Semiconductor ETF is far larger — about 3538.2× Citius Pharmaceuticals Inc's market cap, and iShares Semiconductor ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and iShares Semiconductor ETF for 46 Days on average.
| CTXR | SOXX | |
|---|---|---|
Market Cap | $13.62M | $48.19B |
Volume | 132,438 | 10,257,578 |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $655.01 |
52-Week Low | $0.48 | $268.10 |
Typical Hold Time | 16 Days | 46 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
SOXX trades at $559.40, down 4.04% over the past 24 hours, with technical indicators showing a bullish moving average signal but neutral oscillators. The semiconductor ETF faces mixed sentiment with strong AI-driven earnings growth projections but concerns about valuation premiums. Recent corporate actions include a 1:3 stock split scheduled for November 2026 and a $0.33 dividend payment in September 2026.
The outlook remains cautiously optimistic with AI infrastructure demand driving earnings growth, though high valuations and bearish bets from notable investors like Michael Burry present significant risks. Wall Street analysts maintain positive ratings based on semiconductor market expansion projections, with Bank of America forecasting near-doubling of the global chip market by 2030.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
